Iberdomide Doubles MRD-Negative Complete Response Rate in Relapsed/Refractory Multiple Myeloma Phase 3 Trial

Results from the phase 3 EXCALIBER-RRMM trial, simultaneously published in The Lancet Oncology, indicate that iberdomide (Zenbexus) combined with daratumumab (Darzalex) and dexamethasone (IDd) more than doubled the rate of minimal residual disease (MRD)-negative complete response compared to daratumumab, bortezomib (Velcade), and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma (RRMM). The overall response rate was 88.9% with IDd versus 76.1% with DVd, and the rate of complete response or better was nearly doubled at 45.9% versus 24.9%.